Inpharmation takes an evidence-based approach to international reference pricing (IRP) forecasts, this means all our services:
- Capture the full complexity of the reference pricing system.
- Communicate forecast drivers using clear and simple rules, not vague assumptions.
- Are engineered for efficiency and stability.
The world’s leading pharma companies work with Inpharmation when they need international pricing forecasts built upon a solid evidence-base, including:
- International reference pricing rules database with full global coverage.
- The industry-leading strategic IRP strategy simulator.
- The industry-leading launch optimization engine.
Inpharmation’s international reference pricing simulators have been developed over two decades specifically for the strategic analysis requirements of global pharma pricing and market access teams. Because 7 of the top-10 countries, ranked by pharmaceutical sales, use IRP as part of the pricing and reimbursement agreement process, no pricing strategy can ignore the impact of reference pricing.
“Inpharmation’s approach to IRP offers an intuitive and comprehensive approach to modelling the complexities of the IRP environment.”
“Their tool enables rapid “what-if” scenario analyses that simply could not be investigated without such a tool.”
“From the results we have been able to develop a number of informed strategies that have significantly reduced the impact of price erosions across Europe.”
“Not only is the tool a must have for any pricing/market access team, but also Inpharmation’s knowledge and quick response to our queries has proven invaluable in developing key commercial strategies.”
Top 30 Pharma Company
“It was a pleasure to work with the Inpharmation team, as they were very responsive and always supportive with any upcoming question.”
“The tool offers an enormous amount of options to build up, however if options are missing the team is open to customize it.”
Top 5 Pharma Company
“For any pricing professional, I would highly recommend this IRP tool. Very well designed, robust structure and will definitely save you time.”
Top 30 Pharma Company
What can evidence-based international reference pricing do for you?
Inpharmation has spent decades modelling the growth of the international reference pricing system (sometimes known as the external reference pricing or international price referencing system).
If you are currently modelling the international reference pricing system you will understand the frustration of trying to capture the many different complex elements. Inpharmation’s evidence-based international reference pricing database encompasses a reference pricing system of over 90 countries and 33 different reference pricing methodologies.
All our clients benefit from pricing solutions based on extensively validated models and methodologies.
Inpharmation has approaches for each stage of your pharmaceutical product’s lifecycle. Inpharmation is expert in behavior-based pricing and econometric pricing models for early stage assets, payer summit, payer conjoint and probabilistic van Westendorp for products coming to market. We also have international system models and price-demand elasticity models for products near or past launch.
Inpharmation runs Europe’s leading pharmaceutical pricing for market access executive training courses. In all our projects we place great importance on transferring knowledge and skills to our clients.
The evidence behind Inpharmation’s fact-based approach to pricing is meticulously documented in the book Value Pricing for Market Access: Evidence-Based Pricing for Pharmaceuticals by Inpharmation’s founder and Chairman, Gary Johnson.